Therapeutics based on the eAXON technology

Informacje na temat projektu

TEAXON

Identyfikator umowy o grant: 101112853

DOI

10.3030/101112853

Projekt został zamknięty

Data podpisania przez KE 20 Marca 2023

Data rozpoczęcia 1 Kwietnia 2023

Data zakończenia 30 Września 2024

Finansowanie w ramach

• European Research Council (ERC)

Koszt całkowity

Brak danych

Wkład UE

€ 150 000,00

Koordynowany przez

UNIVERSIDAD POMPEU FABRA
Spain

Periodic Reporting for period 1 - TEAXON (Therapeutics based on the eAXON technology)

Okres sprawozdawczy: 2023-04-01 do 2024-09-30

Podsumowanie kontekstu i ogólnych celów projektu

Within the eAXON project, which was funded by an ERC Consolidator Grant (Grant agreement ID: 724244), we developed and demonstrated wireless microstimulators whose operation is based on rectification of volume conducted bursts of innocuous high-frequency current externally delivered through textile electrodes. In contrast to previous implantable stimulation technologies apt for clinical use, our technology allows the implementation of much thinner implants that can be minimally invasively deployed by injection. For instance, the prototypes we developed within the eAXON project for intramuscular stimulation are threadlike, with a diameter of less than 1 mm, and consist of a silicone tubular body with two electrodes at the opposite ends and a titanium capsule in the middle that hermetically houses the electronics. Such a degree of miniaturization is possible because our technology avoids the need for bulky components within the implants (e.g. batteries or coils).

While the eAXON project concentrated on the potential of the technology for neuromuscular stimulation to restore motor functions in patients with paralysis, the TEAXON project explored its potential for non-motor therapeutic applications involving peripheral nerve stimulation.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

In essence, the actions carried out during the TEAXON project were intended to: 1) clarify the clinical and market potential of the eAXON technology for non-motor peripheral nerve stimulation (PNS), 2) generate intellectual property based on adaptations of the eAXON technology for therapies based on PNS, and 3) reinforce confidence in the robustness of the eAXON technology.

First, the clinical and market potential of eAXON technology for peripheral nerve stimulation (PNS) was analyzed through a comprehensive approach, including existing market studies on PNS, in-depth interviews with experts and key opinion leaders (KOLs), and collaboration with a consultancy firm to develop a strategic market analysis.

Second, a novel therapeutic system based on the use of the eAXON technology was conceived and protected through a patent application. (Further details are intentionally omitted to preserve confidentiality.)

Third, to reinforce confidence in the robustness of the eAXON technology, we have developed test benches and assays to assess durability. In collaboration with an AIMD industry expert, we have also identified essential aspects critical to robustness of the eAXON technology.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

As stated above, a novel therapeutic system based on the use of the eAXON technology was conceived and protected through a patent application. (Further details are intentionally omitted to preserve confidentiality.)

The primary goal of the TEAXON project was to de-risk eAXON technology for peripheral nerve stimulation (PNS) and advance it toward patient use, effectively increasing its value. We recognize that launching a spin-off or startup to further develop and clinically validate the technology is an essential step for any highly innovative medical technology, especially in the field of active implantable medical devices (AIMDs). Consequently, the de-risking activities within the TEAXON project were also intended to lay the groundwork for a future spin-off, reducing risk for potential investors—whether from private sectors or public funding sources such as the EIC Transition program.